NJ State Employees Deferred Compensation Plan’s Regeneron Pharmaceuticals REGN Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500	Closed	-$281K	–	319
2025 Q3	$281K	Hold	500	–	–	0.03%	367
2025 Q2	$263K	Hold	500	–	–	0.03%	366
2025 Q1	$317K	Hold	500	–	–	0.04%	349
2024 Q4	$356K	Hold	500	–	–	0.04%	344
2024 Q3	$526K	Hold	500	–	–	0.06%	280
2024 Q2	$526K	Hold	500	–	–	0.07%	270
2024 Q1	$481K	Hold	500	–	–	0.06%	298
2023 Q4	$439K	Hold	500	–	–	0.06%	309
2023 Q3	$411K	Hold	500	–	–	0.06%	295
2023 Q2	$359K	Hold	500	–	–	0.05%	336
2023 Q1	$411K	Hold	500	–	–	0.06%	321
2022 Q4	$361K	Hold	500	–	–	0.06%	327
2022 Q3	$344K	Hold	500	–	–	0.06%	330
2022 Q2	$296K	Hold	500	–	–	0.05%	357
2022 Q1	$349K	Hold	500	–	–	0.05%	367
2021 Q4	$316K	Hold	500	–	–	0.04%	389
2021 Q3	$303K	Hold	500	–	–	0.04%	393
2021 Q2	$279K	Hold	500	–	–	0.04%	433
2021 Q1	$237K	Hold	500	–	–	0.03%	456
2020 Q4	$242K	Hold	500	–	–	0.04%	421
2020 Q3	$280K	Hold	500	–	–	0.05%	341
2020 Q2	$312K	Hold	500	–	–	0.06%	316
2020 Q1	$244K	Buy	+500	New	+$206K	0.06%	334

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's REGN Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 500 shares — an estimated $281K sold.

NJ State Employees Deferred Compensation Plan first reported a position in REGN in Q1 2020 and held it in 23 quarters. The position peaked at $526K in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 500 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $281K.
NJ State Employees Deferred Compensation Plan first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 23 quarters.
NJ State Employees Deferred Compensation Plan's Regeneron Pharmaceuticals position peaked at $526K in Q3 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.